<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871764</url>
  </required_header>
  <id_info>
    <org_study_id>019002</org_study_id>
    <nct_id>NCT03871764</nct_id>
  </id_info>
  <brief_title>Prediction of Outcome in Severe Preeclampsia</brief_title>
  <official_title>Relation of 3rd Trimester Uterine Artery Doppler Flow Velocimetry Indices, Factor V Leiden Mutation and Placental Pathology to the Severity of Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this summary studied the predictive values of factor V Leiden mutation , doppler indices ,
      placental pathology to unfavorable fetal and maternal outcomes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      leiden mutation is activated protein C resistance with hypercoagulable states and increased
      thrombotic risk. 99 % are heterozygous and 1 % is homozygous , very rare cases are
      psoudohomozygous with factor V deficiency. relation to this mutation was studied in severe
      preeclamptic patients. doppler indices of uterine arteries , increased pulsetility index or
      unilateral or bilateral uterine artery notch and placental pathology were studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>7 Days</target_duration>
  <primary_outcome>
    <measure>percentage of patients develop abruption placenta, intrauterine growth retardation or delivered premature</measure>
    <time_frame>within 12 wks from diagnosis of severe preeclampsia</time_frame>
    <description>placental abruption, prematurity, IUGR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of fetuses and neonates complicated with intrauterine fetal death or need admission to incubator</measure>
    <time_frame>from diagnosis of severe preeclampsia till one week after delivery</time_frame>
    <description>IUFD, admission to neonatal IUC</description>
  </primary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Leiden Factor V Deficiency,Preeclampsia</condition>
  <condition>Doppler Examination</condition>
  <condition>Palental Pathology</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood sample , doppler of uterine vessel and placenta</intervention_name>
    <description>blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples and placental pathology
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women with preeclampsia in 3rd trimester. Singleton pregnancy. Accurate
        gestational age confirmed by last menstrual period or sonography before 20 weeks.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: severe preeclampsia in 3rd trimester -

        Exclusion Criteria:Twin pregnancy. Fetal congenital anomalies. Diabetic patient, impaired
        renal function. Any medical disorders even that HTN. Any placental pathology,Autoimmune
        diseases. Women with uterine activity or clinical emergencies with maternal hemodynamic
        instability or an indication for immediate termination of pregnancy.

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Olfat Nooh Riad Ali</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Factor V Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

